ACC heart failure highlights include progress with LVADs, pulmonary artery sensors
NEW ORLEANS — At the American College of Cardiology Scientific Session, attendees learned about how a new-generation left ventricular assist device improved the lives of patients with advanced HF, how use of a pulmonary artery sensor reduced HF admissions, how the diabetes drug dapagliflozin could benefit patients with HF, and more.
These and other HF-related highlights have been compiled by Cardiology Today.
MOMENTUM 3: Newer LVAD ‘adds life to patients’ years’
NEW ORLEANS — In the final results of the MOMENTUM 3 trial, patients with advanced HF requiring a left ventricular assist device implanted with a continuous centrifugal-flow fully magnetically levitated pump engineered to prevent thrombosis had better outcomes at 2 years than a predecessor device.
CardioMEMS: Pulmonary artery sensor decreases hospitalizations in HF
NEW ORLEANS — Patients with HF who were treated with pulmonary artery pressure-guided therapy through ambulatory hemodynamic monitoring with an implantable sensor had decreases in HF hospitalizations, pulmonary artery pressures and all-cause hospitalizations, according to data presented at the American College of Cardiology Scientific Session.
CV benefits of diabetes drug dapagliflozin extend to patients with reduced ejection fraction
NEW ORLEANS — Treatment with the SGLT2 inhibitor dapagliflozin reduced HF hospitalizations in patients with a broad range of left ventricular ejection fraction and may provide even greater benefit with lower CV death and mortality in patients with HF with reduced ejection fraction, researchers reported at the American College of Cardiology Scientific Session.
Sacubitril/valsartan benefit in acute HF confirmed in extension study
NEW ORLEANS — In the PIONEER-HF extension study of sacubitril/valsartan in patients with acute HF, the therapy was associated with reductions in N-terminal pro-B-type natriuretic peptide at 12 weeks.
Many HFrEF medications are underdosed
NEW ORLEANS — Many eligible patients with HF with reduced ejection fraction do not receive the target dose of their medications, according to data from the CHAMP-HF registry presented at the American College of Cardiology Scientific Session.
PANACHE: Neladenoson unsuccessful in improving walking distance in HFpEF
NEW ORLEANS —A partial adenosine A1 receptor agonist in patients with HF with preserved ejection fraction did not have a dose-response effect for 6-minute walk distance at 20 weeks and other endpoints such as activity levels, ECG monitoring and echocardiographic endpoints, according to data from the PANACHE trial presented at the American College of Cardiology Scientific Session.
Blended treatment for depression, heart failure improves quality of life
NEW ORLEANS — Care composed of treating depression and HF may improve health-related quality of life in the 12 months after hospitalization, according to Hopeful Heart trial findings presented at the American College of Cardiology Scientific Session.
Two biomarkers yield comparable CV risk prediction before, during sacubitril/valsartan treatment
NEW ORLEANS — B-type natriuretic peptide and N-terminal proBNP were equally effective at predicting risk for major adverse CV events in patients with HF with reduced ejection fraction taking sacubitril/valsartan, according to data presented at the American College of Cardiology Scientific Session.
Safety-net hospitals bear brunt of financial penalties for HF readmissions
NEW ORLEANS — Safety-net hospitals, defined as those in socioeconomically disadvantaged areas, are more likely than other hospitals to be penalized by CMS for high 30-day HF readmission rates, according to a presentation at the American College of Cardiology Scientific Session.
Proper self-care leads to better outcomes in HF, but underappreciated
NEW ORLEANS — Self-care plays an important role in outcomes of patients with HF, but is not emphasized by clinicians as much as it should be, a speaker said at the American College of Cardiology Scientific Session.